Table 4.

Summary of studies where pancreatic adenocarcinoma patients with somatic BRCA mutations (sBRCA) were treated with PARP inhibitors.

Clinical Trial	Phase	Treatment	sBRCA	gBRCA	Results
Reiss et al. [79]	2	rucaparib	n = 2	n = 34	PFS 13.1 month; OS 23.5 month; ORR 41.7% Median response: 17.3 months (95% CI: 8.8–25.8). Responses occurred in ½ of the sBRCA2 (50%) and in 11/27 of the gBRCA2 (41%) patients.
Shroff et al. [82]	2	rucaparib	n = 3	n = 16	ORR: 2/3 (67%) for sBRCA and 1/16 (6%) for gBRCA.

gBRCA: germline BRCA mutation; ORR: objective response rate; OS: overall survival; PFS: progression-free survival.